Stephen Brozak analyst WBB

Currently out of the existing stock ratings of Stephen Brozak, 244 are a BUY (71.35%), 44 are a SELL (12.87%), 54 are a HOLD (15.79%).

Stephen Brozak

Work Performance Price Targets & Ratings Chart

Analyst Stephen Brozak works at WBB with a stock forecast success ratio of 52% fulfilled within 80 days on average.

Stephen Brozak’s has documented 33 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CFRX, ContraFect Corp at 08-Jun-2022.

Wall Street Analyst Stephen Brozak

Analyst best performing recommendations are on PRTK (PARATEK PHARMACEUTICALS).
The best stock recommendation documented was for PRTK (PARATEK PHARMACEUTICALS) at 4/23/2021. The price target of $10 was fulfilled within 46 days with a profit of $2.22 (28.53%) receiving and performance score of 6.2.

Average potential price target upside

RDHL Redhill Biopharma Ltd CDTX Cidara Therapeutics PRTK Paratek Pharmaceuticals CFRX ContraFect Corp CWBR CohBar SRPT Sarepta Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

2 years 2 months 21 days ago

0/1 (0%)

$642 (161.31%)

Buy

880

$879.49 (172449.02%)

880

2 years 5 months 8 days ago

0/2 (0%)

$578.6 (230.24%)

480

$479.45 (87172.73%)

640

3 years 3 months 10 days ago

0/2 (0%)

$167.6 (53.65%)

Buy

17

4 years 7 months 10 days ago

0/1 (0%)

$8 (88.89%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Stephen Brozak?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?